Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem for Acute Valproic Acid Toxicity
NCT04671589Phase 4Unknown
- Sponsor
- Mabaret Al-Asafara Hospitals
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of meropenem in valproic acid toxicity, sponsored by Mabaret Al-Asafara Hospitals. Status: unknown.
02
Drugs
meropenem
03
Conditions
valproic acid toxicity
Beyond the preview
Go deeper on NCT04671589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671589.